Monoclonal antibodies for intracellular delivery of payloads
AssigneeOregon Health & Science University
InventorJohn L. Muschler
Life of this patent
Estimating the term…
Abstract
The present disclosure relates to delivering payloads to the interior of a cell. In particular, the present disclosure provides three monoclonal antibodies that bind dystroglycan (DG) on the surface of cells. The antibodies are internalized into endocytic vesicles inside the cells once they are bound to DG. Thus, these antibodies can be used to selectively target and deliver payloads to cells, such as epithelial cells in cancer. The disclosed antibodies bind to DG independent of variable DG glycosylation. The targeted delivery enables selective treatment, imaging, and surveillance of cells in cancer, such as bladder cancer, along with other uses.
Claims92
An isolated antibody or antigen-binding fragment thereof that binds to dystroglycan (DG), comprising:
- (A) a heavy chain comprising:
- CDRH1 set forth in SEQ ID NO:
- 1,
- CDRH2 set forth in SEQ ID NO:
- 2, and
- CDRH3 set forth in SEQ ID NO:
- 3;
- and a light chain comprising:
- CDRL1 set forth in SEQ ID NO:
- 4,
- CDRL2 set forth in SEQ ID NO:
- 5, and
- CDRL3 set forth in SEQ ID NO:
- 6;
- or
- (B) a heavy chain comprising:
- CDRH1 set forth in SEQ ID NO:
- 11,
- CDRH2 set forth in SEQ ID NO:
- 12, and
- CDRH3 set forth in SEQ ID NO:
- 13;
- and a light chain comprising:
- CDRL1 set forth in SEQ ID NO:
- 14,
- CDRL2 set forth in SEQ ID NO:
- 15, and
- CDRL3 set forth in SEQ ID NO:
- 16;
- or
- (C) a heavy chain comprising:
- CDRH1 set forth in SEQ ID NO:
- 21,
- CDRH2 set forth in SEQ ID NO:
- 22, and
- CDRH3 set forth in SEQ ID NO:
- 23;
- and a light chain comprising:
- CDRL1 set forth in SEQ ID NO:
- 24,
- CDRL2 set forth in SEQ ID NO:
- 25, and
- CDRL3 set forth in SEQ ID NO:
- 26;
- wherein the binding is independent of variable DG glycosylation.
Dependencies are inferred from the claim text.